Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.

Li Chia ChongJennifer E HardinghamAmanda R TownsendCynthia PiantadosiGonzalo Tapia RicoChris KarapetisRob PadburyGuy MaddernAmitesh RoyTimothy Jay Price

Published in: Targeted oncology (2021)

Anti-EGFR rechallenge provides clinical benefit in patients with RAS wild-type metastatic CRC.

Keyphrases

wild type
small cell lung cancer
metastatic colorectal cancer
epidermal growth factor receptor
tyrosine kinase
squamous cell carcinoma
bone marrow
mesenchymal stem cells